Navigation Links
CNIO researchers discover a new therapy that prevents lung cancer growth in mice
Date:8/13/2012

Lung cancer is one of the most aggressive types of cancer and the most common cause of death from this disease worldwide. Despite the progress in the molecular biology of lung cancer achieved in recent years, the mechanisms used by tumor cells to grow and spread throughout the body are not yet completely understood. This lack of information is responsible for the limited range of available therapeutic possibilities and their undesirable side effects.

The Tumour Suppression Group of the Spanish National Cancer Research Centre (CNIO), led by Manuel Serrano, has deciphered one of the molecular pathways behind lung cancer. Using this information, the authors have identified an experimental drug, which blocks lung cancer growth in mice. This work is published today in the scientific journal Cancer Cell.

Standing up to lung cancer

Notch was identified in 2004 as an important oncogene for the development of leukemias and, since then, intense efforts have been devoted to study the role of Notch in other cancers. At the end of the last decade it was found that Notch is also involved in the development of pancreatic and lung cancer.

In this study, Serrano's team has identified the molecular pathways by which Notch regulates cell proliferation in lung cancer. "We have found that this protein cooperates with the Ras oncogene, a key element in the formation of these tumors", states Serrano.

Researchers have also discovered the therapeutic effect of a specific experimental drug which blocks Notch efficiently, named GSIs (Gamma-Secretase Inhibitors). To this end, scientists used genetically modified mice previously developed by Mariano Barbacid, head of the Experimental Oncoloy Group at the CNIO, that faithfully recapitulate human lung cancer. "After 15 days of treatment, lung tumors failed to grow without treatment-related side effects", says Antonio Maraver, the first author of the study.

Co-clinical trials both in humans and mice

GSIs were developed over 15 years ago to treat Alzheimer's disease. Although now it is well established that GSIs are not useful to stop this neurodegenerative disease, the discovery that these drugs block Notch has stirred the interest in their possible application for cancer. The accumulated knowledge acquired over the years on the pharmacological properties of GSIs has permitted their immediate use in clinical trials for cancer.

Mouse therapeutic trials performed in parallel with humans clinical trials are called coclinical trials, and are at the cutting edge of biomedical research. These trials allow the transference of information from mice to humans in a very short period of time. A clear example is this research, which is being accompanied by a human clinical trial led by Manuel Hidalgo, director of the Clinical Research Program at the CNIO.

"The assays developed by Serrano led us to believe that blocking Notch could be beneficial for treating lung cancer. We have already treated a dozen patients with an agent directed at the blocking of this protein. We are expanding the study, but I can anticipate that the results are very promising", says Hidalgo.


'/>"/>
Contact: Nuria Noriega
nnoriega@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)
Source:Eurekalert

Related medicine news :

1. BUSM researchers part of multi-center study on cardiac amyloidosis
2. BUSM/VA researchers uncover gender differences in the effects of long-term alcoholism
3. Excellence Initiative winner TU München invests in the future: Young researchers
4. Clemson researchers collect and reuse enzymes while maintaining bioactivity
5. Healthcare researchers recognized at SingHealth Duke-NUS Scientific Congress 2012
6. Northwestern researchers investigate treatment for tumor cells in spinal fluid
7. Vanderbilt researchers find proteins may point way to new prostate cancer drug targets
8. MDC researchers develop new approach to treat acute liver failure
9. Breast Cancer Charity Overstates Value of Mammograms: Researchers
10. Boston University researchers expand synthetic biologys toolkit
11. Global health researchers urge integrating de-worming into HIV care in Africa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... August 23, 2017 , ... ... (SNAC) is holding an inaugural State of the Science Symposium in partnership with ... Sept. 20, 2017. , This symposium provides a forum for global leaders in ...
(Date:8/22/2017)... ... August 22, 2017 , ... Western North Carolina’s only certified ... international aesthetics conference for medical professionals about the positive impact Juliet™ feminine ... growing practice. , Dr. George K. Ibrahim shared the results of ...
(Date:8/22/2017)... ... August 22, 2017 , ... Nurses at Apple Rehab Watch ... Cove, recently received training and certification in Closed Pulse Irrigation™ (CPI) for ... five-star rating from the Centers for Medicare and Medicaid Services, to have a CPI ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... ... heart-wrenching story of child abuse and neglect, and the struggles faced while hoping ... is the creation of published author, Judy Von Bernewitz, who spent 13 years ...
(Date:8/22/2017)... ... August 22, 2017 , ... TopConsumerReviews.com recently gave a ... fight Fatigue . , As the stress of modern life continually makes more demands ... Constant use of artificial stimulants can trap people in vicious high/low cycles and can ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... -- Endo International plc (NASDAQ: ENDP ) today ... known U.S. mesh product liability claims and that it ... U.S. claims at reasonable values. Under the agreements, Endo ... of 2017 and continuing through the fourth quarter of ... the Company intends to increase its mesh product liability ...
(Date:8/2/2017)... Fenita J. Caldwell is ... Lifetime Professional in the Field of Healthcare. Caldwell ... Pharmaceuticals, AG. Her skills and areas of expertise ... Fenita ... experience as a highly successful sales specialist in ...
(Date:8/1/2017)... Aug. 1, 2017   CerSci Therapeutics , a ... Texas , has received notice from the National ... of Health (NIH) that it has been awarded a ... over $650,000 in 2017 with an additional $1,000,000 to ... New Drug application of their lead non-opioid drug candidate ...
Breaking Medicine Technology: